Strongbridge Biopharma plc (NASDAQ:SBBP) is set to announce third quarter earning results on Thursday 29th October 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, SBBP to report 3Q20 loss of $ 0.13 per share.
For the full year, analysts anticipate top line of $ 27.80 million, while looking forward to loss of $ 0.58 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 28.00 million ~ $ 29.00 million
Click Here For More Historical Outlooks Of Strongbridge Biopharma plc
Previous Quarter Performance
Strongbridge Biopharma plc revealed loss for the second quarter of $ 0.12 per share, from the revenue of $ 7.76 million. The quarterly revenues escalated 64.06 percent compared with the same quarter last year. Wall street analysts are predicting, SBBP to report 2Q20 loss of $ 0.21 per share from revenue of $ 6.00 million. The bottom line results beat street analysts by $ 0.09 or 42.86 percent, at the same time, top line results outshined analysts by $ 1.76 million or 29.33 percent.
Stock Performance
Shares of Strongbridge Biopharma plc traded low $ -0.08 or -4.02 percent on Wednesday, reaching $ 1.91 with volume of 608.20 thousand shares. Strongbridge Biopharma plc has traded high as $ 2.00 and has cracked $ 1.88 on the downward trend
According to the previous trading day, closing price of $ 1.91, representing a 39.16 % increase from the 52 week low of $ 1.43 and a 57.02 % decrease over the 52 week high of $ 4.63.
The company has a market capital of $ 125.04 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Strongbridge Biopharma plc will be hosting a conference call at 4:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.strongbridgebio.com
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The companys commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushings syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly.
